Medtronic plc research snapshot
MDT AI stock analysis reads Medtronic plc as a durable global medical technology business whose FY2026 revenue growth improved, but whose stock still needs disciplined execution after the MiniMed separation, tariff pressure, tax matters, and long-cycle device regulation. At the August 2, 2026 data cutoff, MDT closed near $85.39 on July 31, 2026, had a reported market capitalization near $109.30 billion, and produced FY2026 revenue of $36.364 billion with $5.426 billion of free cash flow. Analysts upgraded the outlook in late July 2026, but the stock still trades below its 200-day moving average, so the technical trend is mixed. This MDT AI stock analysis uses scenario ranges, not a guaranteed price prediction, and it is informational research rather than investment advice.
Current price
$85.39
Market cap
$109.30 billion reported, $109.31 billion calculated
AI score
77 / 100
Rating
Large-cap medtech compounder with improving growth, a mixed technical setup, and valuation discipline still required
Trend status
Mixed technical setup: price is above the 50-day moving average near $80.81 but below the 200-day moving average near $90.11 in the StockAnalysis daily snapshot
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Medtronic sells device-based therapies across cardiovascular, neuroscience, medical surgical, and diabetes categories, serving hospitals, physicians, and patients with recurring procedure demand. | High |
| Moat | The moat comes from clinical evidence, regulatory approvals, physician training, installed workflows, manufacturing quality, global distribution scale, and a deep product portfolio. | High |
| Management | Management delivered the strongest annual revenue growth in a decade in FY2026, completed the MiniMed IPO, and closed the Scientia Vascular and SPR acquisitions, but the next test is converting pipeline breadth into margin and per-share value. | Medium-high |
| Financial trend | FY2026 net sales rose 8.4% to $36.364 billion, GAAP EPS rose to $3.73, non-GAAP EPS was $5.53, cash from operations reached $7.330 billion, and free cash flow reached $5.426 billion. | High |
| Valuation | At $85.39, MDT trades near 22.9x GAAP EPS, 14.35x the FY2027 adjusted EPS guidance midpoint, 20.1x free cash flow per share, and a 3.37% dividend yield. | High for math, medium for forward value |
| Technical trend | The chart is mixed. StockAnalysis showed MDT above its 50-day moving average near $80.81 with RSI near 57.96, but below its 200-day moving average near $90.11 and below the 52-week high. | Medium |
| Risk level | Risk is medium because procedure demand, product approvals, recalls, reimbursement, tariffs, tax disputes, debt, and MiniMed separation outcomes can affect earnings quality. | Medium-high |
| AI confidence | The data set is strong, but much of the stock debate depends on forward organic growth, margin recovery, pipeline timing, and market multiples rather than static historical facts. | High data confidence |
| Investment certainty | MDT has the shape of a quality medtech holding, but the buy case needs evidence that FY2026 growth is durable and that FY2027 EPS guidance is achievable without sacrificing investment. | Medium |
MDT AI stock forecast
The MDT AI stock forecast uses scenario math around the $85.39 price reference, FY2027 adjusted EPS guidance midpoint near $5.95, and a three-year earnings multiple framework. The audited model produced a bearish area near $78, a base area near $105, and a bullish area near $138 before dividends and future capital allocation effects.
$130 to $140
More likely if Cardiovascular growth stays strong, Affera and other ablation platforms keep momentum, Hugo and other pipeline assets scale, tariffs are managed, MiniMed value is clarified, and investors assign a high-teens to 20x earnings multiple.
$100 to $110
More likely if organic revenue grows near the FY2027 guide, adjusted EPS compounds around mid-single to high-single digits, free cash flow conversion remains solid, and MDT holds a mid-teens earnings multiple.
$75 to $80
More likely if revenue growth slows, product launches disappoint, reimbursement or regulatory issues appear, tax or litigation reserves expand, or the market prices MDT closer to a low-teens earnings multiple.
MDT AI technical analysis
MDT AI technical analysis is mixed as of the August 2, 2026 cutoff. StockAnalysis showed MDT at $85.39, a day range of $83.84 to $85.97, a 52-week range of $73.31 to $106.33, RSI near 57.96, a 50-day moving average near $80.81, and a 200-day moving average near $90.11. Price holding above the 50-day average is constructive, but the 200-day average overhead is a hurdle the stock has not cleared.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $85.39 | StockAnalysis listed MDT at $85.39 at the July 31, 2026 close, near the August 2, 2026 data cutoff. |
| Immediate support | $83.84 to $85.00 | The July 31 day low of $83.84 and the area just below the close are the near-term floor. A break below it would weaken the short-term setup. |
| Trend support | $80.81 | This is the cited 50-day moving average. Holding above it supports the current recovery read, and it becomes a first downside reference. |
| Deeper support | $73.31 | The cited 52-week low is the major downside reference if the recovery fails. |
| Near resistance | $90.11 | The cited 200-day moving average sits above price and is the first major upside hurdle. |
| Longer resistance | $98.44 to $106.33 | The lower area is the StockAnalysis average price target and the upper area is the cited 52-week high. |
| Momentum | RSI near 57.96 | The daily snapshot showed a neutral to slightly constructive RSI without an extreme overbought reading. |
| Volume and volatility | Medium monitoring priority | Earnings on September 1, 2026, FY2027 guidance updates, product approvals, and MiniMed separation details can change the setup. |
| Invalidation | Close below $80.81, then $73.31 | A close below the 50-day area would weaken the trend-following case. A move below the 52-week low would invalidate the recovery framework. |
MDT AI trading strategy
The MDT AI trading strategy below is a rules-based research framework, not personal advice. It connects Medtronic fundamentals, FY2027 guidance, dividend and cash flow quality, and technical confirmation with predefined invalidation levels.
Watch for MDT to hold above the $81 moving-average support and push through the $90 to $98 resistance zone. Confirmation should include stable FY2027 EPS guidance, strong Cardiovascular growth, and no adverse update on MiniMed, tax, or regulatory matters.
A failed breakout followed by a close below the 50-day moving average area should reduce setup confidence because it would show the recovery lacks institutional follow-through.
If MDT pulls back toward $81 without a guidance cut, compare the selloff with cash flow, dividend coverage, procedure-volume commentary, Cardiovascular growth, Diabetes separation news, and medtech peer performance.
Do not treat weakness as benign if it is tied to lower FY2027 guidance, product safety issues, reimbursement pressure, or a material increase in tax or litigation exposure.
Track organic revenue growth, adjusted EPS, free cash flow, operating margin, Cardiovascular growth, neuroscience growth, medical surgical margin, R&D pipeline progress, share repurchases, debt reduction, and MiniMed disclosures.
Position sizing should reflect device regulation, product recall risk, long sales cycles, payer pressure, tariffs, tax reserves, and the fact that dividend stability does not remove equity drawdown risk.
Investment research summary
Medtronic is paid because hospitals and physicians need reliable devices and therapies that treat heart disease, neurological disorders, surgical conditions, and diabetes care needs. The customer value is clinical reliability, procedure support, and patient outcomes.
Medtronic has brand trust among clinicians, high switching friction inside procedure workflows, regulatory approvals, manufacturing scale, clinical data, global sales reach, and technology platforms in cardiac rhythm, ablation, spine, surgical tools, and diabetes.
The thesis fails if growth platforms do not scale, product quality slips, regulators delay approvals, payers pressure device economics, tax liabilities expand, MiniMed separation creates distraction, or debt limits capital allocation flexibility.
Management under CEO Geoff Martha has pushed portfolio focus, growth-driver investment, the MiniMed IPO, the Scientia Vascular and SPR acquisitions, dividends, and buybacks. The key capital allocation question is whether R&D, acquisitions, dividends, debt, and repurchases create per-share value together.
Aging populations, chronic disease, minimally invasive procedures, cardiac ablation, robotic and digital surgery, remote monitoring, and diabetes technology support long-term medtech demand. Regulation, reimbursement, and hospital budgets are the counterweights.
At $85.39, MDT is not priced like a high-growth medtech stock, but the margin of safety depends on FY2027 adjusted EPS near $5.90 to $6.00, organic growth near guidance, and free cash flow remaining strong enough to fund dividends and reinvestment.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $85.39 at the July 31, 2026 close | StockAnalysis MDT quote (S&P Global/CBOE data) | August 2, 2026 |
| Shares outstanding | 1,280,177,293 ordinary shares issued and outstanding as of April 24, 2026 | Medtronic FY2026 Form 10-K | August 2, 2026 |
| Market capitalization verification | $109.31 billion calculated from $85.39 x 1,280,177,293 shares, compared with $109.30 billion reported reference | Pineify financial_rigor.py and StockAnalysis market cap reference | August 2, 2026 |
| FY2026 net sales | $36.364 billion, up 8.4% as reported and 5.8% organic | Medtronic FY2026 Form 10-K and FY2026 earnings release | August 2, 2026 |
| FY2026 net income attributable to Medtronic | $4.801 billion, GAAP diluted EPS $3.73 | Medtronic FY2026 Form 10-K | August 2, 2026 |
| FY2026 non-GAAP diluted EPS | $5.53, up 0.7% | Medtronic FY2026 earnings release | August 2, 2026 |
| FY2026 free cash flow | $5.426 billion from $7.330 billion operating cash flow | Medtronic FY2026 earnings release | August 2, 2026 |
| Cash and current investments | $9.220 billion, including $1.949 billion cash and $7.271 billion investments | Medtronic FY2026 Form 10-K | August 2, 2026 |
| Debt | $1.788 billion current debt obligations and $26.173 billion long-term debt, about $28.0 billion total debt at April 24, 2026 | Medtronic FY2026 Form 10-K | August 2, 2026 |
| FY2026 segment structure | Cardiovascular, Neuroscience, Medical Surgical, and consolidated MiniMed diabetes business | Medtronic FY2026 Form 10-K | August 2, 2026 |
| Q4 FY2026 segment revenue | Cardiovascular $3.797 billion, Neuroscience $2.751 billion, Medical Surgical $2.388 billion, Diabetes $837 million | Medtronic FY2026 earnings release | August 2, 2026 |
| Technical snapshot | RSI 57.96, 50-day moving average $80.81, 200-day moving average $90.11 | StockAnalysis MDT statistics page | August 2, 2026 |
| FY2027 guidance | Organic revenue growth guidance 6.75% to 7.25% and adjusted EPS guidance $5.90 to $6.00 | Medtronic FY2026 earnings release | August 2, 2026 |
| Analyst consensus | Buy rating from 29 analysts with an average price target of $98.44 as of late July 2026 | StockAnalysis MDT forecast page | August 2, 2026 |
| Upcoming earnings | Q1 FY2027 results scheduled for September 1, 2026 | Medtronic newsroom announcement | August 2, 2026 |
This MDT AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of August 2, 2026 and may be wrong if Medtronic guidance, product approvals, regulatory outcomes, market multiples, interest rates, or investor sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
